Caramori Maria Luiza, Canani Luis Henrique, Costa Luciana A, Gross Jorge Luiz
Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Diabetes. 2003 Dec;52(12):3010-3. doi: 10.2337/diabetes.52.12.3010.
The peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism has been associated with a decreased risk of type 2 diabetes and a lower albumin excretion rate (AER) in patients with established diabetes. We performed a case-control study aiming to evaluate the association between the Pro12Ala polymorphism and diabetic nephropathy. Genomic DNA was obtained from 104 type 2 diabetic patients (case subjects) with chronic renal insufficiency (78 on dialysis and 26 with proteinuria [AER >or=200 microg/min] and serum creatinine >or=2.0 mg/dl) and 212 normoalbuminuric patients (AER <20 microg/min) with known diabetes duration >or=10 years (control subjects). The genotypic distribution of the PPARgamma2 Pro12Ala polymorphism in these diabetic patients was in Hardy-Weinberg equilibrium, and the Ala allele frequency was 9%. The frequency of Ala carriers (Ala/Ala or Ala/Pro) was 20.3% in control subjects and 10.6% in case subjects (P = 0.031). The odds ratio of having diabetic nephropathy for Ala carriers was 0.465 (95% CI 0.229-0.945; P = 0.034). Carriers of the Ala allele were not different from noncarriers (Pro/Pro) regarding sex (38.9 vs. 44.1% males) or ethnicity (77.4 vs. 71.7% white) distribution, age (61 +/- 10 vs. 61 +/- 10 years), known diabetes duration (17 +/- 7 vs. 16 +/- 7 years), BMI (27 +/- 4 vs. 28 +/- 5 kg/m(2)), fasting plasma glucose (184 +/- 81 vs. 176 +/- 72 mg/dl), HbA(1c) (6.7 +/- 2.3 vs. 6.9 +/- 2.4%; high-performance liquid chromatography reference range: 2.7-4.3%), and systolic (145 +/- 27 vs. 0.144 +/- 24 mmHg) or diastolic (87 +/- 14 vs. 85 +/- 14 mmHg) blood pressure, respectively. In conclusion, the presence of the Ala allele may confer protection from diabetic nephropathy in patients with type 2 diabetes.
过氧化物酶体增殖物激活受体γ2（PPARγ2）Pro12Ala多态性与2型糖尿病风险降低以及已确诊糖尿病患者较低的白蛋白排泄率（AER）相关。我们进行了一项病例对照研究，旨在评估Pro12Ala多态性与糖尿病肾病之间的关联。从104例患有慢性肾功能不全的2型糖尿病患者（病例组）中获取基因组DNA（78例接受透析，26例有蛋白尿[AER≥200μg/min]且血清肌酐≥2.0mg/dl），以及212例已知糖尿病病程≥10年的正常白蛋白尿患者（AER<20μg/min）（对照组）。这些糖尿病患者中PPARγ2 Pro12Ala多态性的基因型分布符合哈迪-温伯格平衡，Ala等位基因频率为9%。Ala携带者（Ala/Ala或Ala/Pro）在对照组中的频率为20.3%，在病例组中为10.6%（P = 0.031）。Ala携带者患糖尿病肾病的优势比为0.465（95%CI 0.229 - 0.945；P = 0.034）。Ala等位基因携带者与非携带者（Pro/Pro）在性别（男性分别为38.9%对44.1%）、种族（白人分别为77.4%对71.7%）分布、年龄（61±10对61±10岁）、已知糖尿病病程（17±7对16±7年）、体重指数（27±4对28±5kg/m²）、空腹血糖（184±81对176±72mg/dl）、糖化血红蛋白（6.7±2.3对6.9±2.4%；高效液相色谱参考范围：2.7 - 4.3%）以及收缩压（145±27对144±24mmHg）或舒张压（87±14对85±14mmHg）方面均无差异。总之，Ala等位基因的存在可能使2型糖尿病患者免受糖尿病肾病的影响。
